Antivirulence Therapeutics Global Market Report 2026

Antivirulence therapeutics are a category of treatments designed to target and inhibit the virulence factors produced by pathogens rather than directly eliminating or suppressing their growth. These therapies operate by disabling the mechanisms that enable microbes to cause disease, thereby reducing their pathogenicity and allowing the body's immune system to remove the infection more effectively.

The primary product types of antivirulence therapeutics consist of small molecule inhibitors, monoclonal antibodies, peptides, and other product types. Small molecule inhibitors are low-molecular-weight compounds developed to inhibit pathogen virulence factors without directly eliminating the pathogens, thereby helping to reduce the likelihood of resistance development. These products are categorized by pathogen type, including bacterial, viral, fungal, and other pathogen types, and are administered through oral, injectable, and other routes of administration. They are applied in areas such as hospital-acquired infections, community-acquired infections, and other conditions, and are utilized by end users including hospitals, clinics, research institutes, and others.

Tariffs are influencing the antivirulence therapeutics market by raising the cost of imported advanced biologic raw materials, peptide synthesis inputs, and specialized laboratory equipment used in infectious disease drug development. This is slowing research and commercialization efforts for pharmaceutical companies, biotechnology firms, and research institutes, particularly in import-dependent regions such as Asia-Pacific and Europe. Segments such as monoclonal antibodies, peptide-based antivirulence agents, and bacteriophage therapies are most affected due to reliance on globally sourced biomanufacturing inputs. However, tariffs are also promoting local biologics production, strengthening regional biotech ecosystems, and accelerating investment in domestic antimicrobial innovation pipelines, ultimately improving long-term supply chain resilience.

The antivirulence therapeutics market size has grown rapidly in recent years. It will grow from $1.45 billion in 2025 to $1.68 billion in 2026 at a compound annual growth rate (CAGR) of 15.8%. The growth in the historic period can be attributed to rising global antimicrobial resistance, growing burden of hospital- and community-acquired infections, limitations of conventional antibiotic therapies, increasing funding for infectious disease research, expansion of microbiology and pathogen genomics studies.

The antivirulence therapeutics market size is expected to see rapid growth in the next few years. It will grow to $3.04 billion in 2030 at a compound annual growth rate (CAGR) of 16.0%. The growth in the forecast period can be attributed to rising demand for alternative non-antibiotic therapies, increasing adoption of precision infectious disease treatments, expansion of antimicrobial stewardship programs, growth in bacteriophage and biologics-based therapeutics, and advancements in AI-based pathogen and virulence modeling technologies. Major trends in the forecast period include precision medicine approaches for targeted antivirulence drug design, cloud-based genomic and pathogen data integration for infectious disease research, IoT-enabled real-time infection surveillance and outbreak tracking systems, Industry 4.0-enabled automated antimicrobial and antivirulence compound screening platforms, and an increasing shift toward non-bactericidal therapeutic strategies to mitigate antimicrobial resistance.

The growing prevalence of hospital-acquired infections is anticipated to drive the expansion of the antivirulence therapeutics market in the coming years. Hospital-acquired infections (HAIs) refer to infections that patients acquire while receiving medical care in a healthcare facility, which were neither present nor incubating at the time of admission. The increasing occurrence of HAIs is attributed to inadequate infection control practices such as poor hand hygiene, improper sterilization of medical equipment, and non-adherence to standard safety protocols, all of which facilitate the transmission of pathogens within healthcare environments. Antivirulence therapeutics mitigate hospital-acquired infections by interfering with bacterial virulence mechanisms such as toxin production, adhesion, and quorum sensing, thereby reducing pathogen pathogenicity and disease severity without directly killing the bacteria and helping limit the emergence of antimicrobial resistance. For instance, in November 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2022-23, hospital-acquired complications (HACs) occurred in 115,000 public hospitalizations (2.0%) and 34,200 private hospitalizations (0.8%). The most common complication was healthcare-associated infection (37%), followed by delirium (13%) and cardiac complications (12%). Therefore, the increasing prevalence of hospital-acquired infections is expected to drive the growth of the antivirulence therapeutics market.

The rising antimicrobial resistance is expected to drive the growth of the antivirulence therapeutics market in the coming years. Antimicrobial resistance (AMR) refers to the ability of microorganisms such as bacteria, viruses, fungi, and parasites to resist the effects of medicines that were previously effective in treating the infections they cause. The increasing antimicrobial resistance is driven by the excessive and inappropriate use of antibiotics in humans and livestock, which accelerates the survival and spread of drug-resistant microorganisms. Antivirulence therapeutics help reduce the selective pressure that contributes to antimicrobial resistance by targeting bacterial virulence mechanisms rather than directly killing pathogens, thereby limiting the emergence and spread of resistant strains. For instance, in November 2025, according to the UK Health Security Agency, a UK-based government agency, the burden of antimicrobial resistance (AMR), measured by population-level incidence of antibiotic-resistant infections in key public health organisms, increased by 9.3% compared with 2023 levels. Therefore, the rising antimicrobial resistance is expected to drive the growth of the antivirulence therapeutics market.

Leading companies operating in the antivirulence therapeutics market are focusing on advancing clinical trials to develop innovative solutions, such as toxin-neutralizing anti-virulence agents to inhibit bacterial pathogenic mechanisms without killing the microbes, thereby reducing disease severity and limiting antimicrobial resistance. Toxin-neutralizing anti-virulence agents are therapeutic compounds that target and inactivate bacterial toxins or virulence factors rather than killing the bacteria, thereby reducing their ability to cause disease while minimizing the risk of antimicrobial resistance. For example, in November 2023, Eagle Pharmaceuticals Inc., a US-based pharmaceutical company, announced the presentation of its ongoing CAL02 Phase 2 clinical trial progress at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. The investigational therapy CAL02 is designed as an anti-virulence treatment that neutralizes bacterial toxins rather than directly killing bacteria, aiming to reduce disease severity and complement existing antibiotic therapies. This development highlights the company's focus on addressing antimicrobial resistance by advancing novel adjunctive treatment approaches for severe bacterial infections such as community-acquired pneumonia.

Major companies operating in the antivirulence therapeutics market are GSK plc, Shionogi & Co. Ltd., AstraZeneca, Bicycle Therapeutics plc, BiomX Inc., PHAXIAM Therapeutics S.A., Armata Pharmaceuticals Inc., Eligo Bioscience SAS, LimmaTech Biologics AG, Aurobac Therapeutics SAS, Micreos Pharmaceuticals AG, Locus Biosciences, BioVersys GmbH, Phagelux Inc., Intralytix Inc., Clarametyx Biosciences, Precisio Biotix Therapeutics Inc., Microbiotix Inc., Red Queen Therapeutics, Technophage S.A., NanoViricides Inc., Inhalon Biopharma, Centauri Therapeutics

North America was the dominant region in the antivirulence therepeutics market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in antivirulence therapeutics report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antivirulence therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antivirulence therapeutics market consists of sales of bacteriophage-based therapies, nucleic acid-based therapies, anti-toxin and immune-modulating biologics, and host-directed therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The antivirulence therapeutics market research report is one of a series of new reports from The Business Research Company that provides antivirulence therapeutics market statistics, including antivirulence therapeutics industry global market size, regional shares, competitors with a antivirulence therapeutics market share, detailed antivirulence therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the antivirulence therapeutics industry. This antivirulence therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antivirulence Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses antivirulence therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antivirulence therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The antivirulence therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Small Molecule Inhibitors; Monoclonal Antibodies; Peptides; Other Product Types
• 2) By Pathogen Type: Bacterial; Viral; Fungal; Other Pathogen Types
• 3) By Route Of Administration: Oral; Injectable; Other Routes Of Administration
• 4) By Application: Hospital Acquired Infections; Community Acquired Infections; Other Applications
• 5) By End User: Hospitals; Clinics; Research Institutes; Other End Users
• Subsegments:
• 1) By Small Molecule Inhibitors: Quorum Sensing Inhibitors; Toxin Production Inhibitors; Biofilm Formation Inhibitors; Secretion System Inhibitors; Adhesion Inhibitors; Enzyme Activity Inhibitors
• 2) By Monoclonal Antibodies: Toxin Neutralizing Antibodies; Surface Protein Targeting Antibodies; Adhesion Blocking Antibodies; Immune Modulating Antibodies; Pathogen Specific Antibodies; Virulence Factor Targeting Antibodies
• 3) By Peptides: Antimicrobial Peptides; Anti Biofilm Peptides; Host Defense Peptides; Membrane Disrupting Peptides; Virulence Suppressing Peptides; Synthetic Therapeutic Peptides
• 4) By Other Product Types: Bacteriophage Therapies; Endolysin Therapies; Antisense Oligonucleotide Therapies; Engineered Protein Therapeutics; Nanoparticle Based Therapeutics; Microbiome Based Therapeutics
• Companies Mentioned: GSK plc; Shionogi & Co. Ltd.; AstraZeneca; Bicycle Therapeutics plc; BiomX Inc.; PHAXIAM Therapeutics S.A.; Armata Pharmaceuticals Inc.; Eligo Bioscience SAS; LimmaTech Biologics AG; Aurobac Therapeutics SAS; Micreos Pharmaceuticals AG; Locus Biosciences; BioVersys GmbH; Phagelux Inc.; Intralytix Inc.; Clarametyx Biosciences; Precisio Biotix Therapeutics Inc.; Microbiotix Inc.; Red Queen Therapeutics; Technophage S.A.; NanoViricides Inc.; Inhalon Biopharma; Centauri Therapeutics
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.